Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

• S. Flamarique ^[1] ; M. Campo ^[1] ; G. Asín ^[1] ; S. Pellejero ^[1] ; A. Viúdez ^[1] ; F. Arias ^[1]
  1. [1] Gobierno de Navarra

     Gobierno de Navarra

     Pamplona, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 12 (December), 2020, págs. 2350-2356
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose We analysed our initial experience with SBRT in liver metastasis from colorectal cancer at our institution.

    Materials and methods Between January/2014 and December/2017, 22 patients with 31 LMCCR were treated. Local control (LC) was assessed using the Kaplan–Meier and log-rank tests. We analysed potential prognostic factors for LC: sex, PTV size, number of LM and the radiation scheme.

    Results Median age: 69 years. Prior chemotherapy or local liver treatments: 81.8% and 63.6% of patients, respectively. SBRT consisted of 3 × 20 Gy (42.9%) and 3 × 15 Gy (31.4%). There were 88.5% responses (57.1% CR and 31.4% PR). Median follow-up was 30 months. LC per lesion at 12 and 24 months was 85.3% and 61.8%, respectively. Tumour volumes > 30 cc correlated with worsened 2-year-control rates (90% vs 34.5%) (p = 0.005). There was only a patient with CTC-grade 3 toxicity.

    Conclusions Liver SBRT is a safe and effective treatment that achieves high local control rates. We found a significant correlation between larger LMCRC and worse local control.